DaVita Inc. which can be found using ticker (DVA) have now 8 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 102 and 74 calculating the mean target price we have $87.49. Given that the stocks previous close was at $83.96 this would indicate that there is a potential upside of 4.2%. Also worth taking note is the 50 day moving average now sits at $80.89 and the 200 day MA is $81.92. The company has a market capitalization of $7,581m. Company Website: https://www.davita.com
The potential market cap would be $7,900m based on the market consensus.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 14.76, revenue per share of 124.85 and a 4.82% return on assets.
